ArticleScientific reports2022
Plasma protein biomarker model for screening Alzheimer disease using multiple reaction monitoring-mass spectrometry.
Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- Vitronectin Modulates Plasma Aβ Oligomerization Propensity Within Altered Albumin Interactome Networks in Alzheimer's Disease.International journal of molecular sciences · 2026Article
- Omics-driven strategies for identifying biomarkers in Alzheimer's disease.Metabolic brain disease · 2026Review
- A Novel Spectral Barcoding and Classification Approach for Complex Biological Samples Using Multiexcitation Raman Spectroscopy (MX-Raman).Analytical chemistry · 2025Article
- LC-MS/MS proteomics identifies plasma proteins related to cognition over 9-year follow-up.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Direct and selective nanosensor for amyloid-β oligomers in serum for Alzheimer's disease diagnosis.RSC advances · 2025Article
- Plasma protein risk scores for mild cognitive impairment and Alzheimer's disease in the Framingham heart study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Exploring peripheral fluid biomarkers for early detection of Alzheimer's disease in Down syndrome: A literature review.Heliyon · 2025Review
- Blood-based biomarkers of Alzheimer's disease: Standardization and comprehensiveness.Neuroprotection (Chichester, England) · 2024Review
- Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Alzheimer's disease CSF biomarkers correlate with early pathology and alterations in neuronal and glial gene expression.medRxiv : the preprint server for health sciences · 2024Article
- Article
- Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status.Journal of Alzheimer's disease : JAD · 2024Article
- Advancing the early detection of canine cognitive dysfunction syndrome with machine learning-enhanced blood-based biomarkers.Frontiers in veterinary science · 2024Article
- Discovery of plasma biomarkers related to blood-brain barrier dysregulation in Alzheimer's disease.Frontiers in bioinformatics · 2024Article
- Detection of Alzheimer's Disease Using Logistic Regression and Clock Drawing Errors.Brain sciences · 2023Article
- βNature neuroscience · 2023Article
- Translational and Posttranslational Dynamics in a Model Peptidergic System.Molecular & cellular proteomics : MCP · 2023Article
- Association of blood pressure variability during acute care hospitalization and incident dementia.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 1 country.
Funding
Abstract
Alzheimer disease (AD) is a leading cause of dementia that has gained prominence in our aging society. Yet, the complexity of diagnosing AD and measuring its invasiveness poses an obstacle. To this end, blood-based biomarkers could mitigate the inconveniences that impede an accurate diagnosis. We developed models to diagnose AD and measure the severity of neurocognitive impairment using blood protein biomarkers. Multiple reaction monitoring-mass spectrometry, a highly selective and sensitive approach for quantifying targeted proteins in samples, was used to analyze blood samples from 4 AD groups: cognitive normal control, asymptomatic AD, prodromal AD), and AD dementia. Multimarker models were developed using 10 protein biomarkers and apolipoprotein E genotypes for amyloid beta and 10 biomarkers with Korean Mini-Mental Status Examination (K-MMSE) score for predicting Alzheimer disease progression. The accuracies for the AD classification model and AD progression monitoring model were 84.9% (95% CI 82.8 to 87.0) and 79.1% (95% CI 77.8 to 80.5), respectively. The models were more accurate in diagnosing AD, compared with single APOE genotypes and the K-MMSE score. Our study demonstrates the possibility of predicting AD with high accuracy by blood biomarker analysis as an alternative method of screening for AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.